Jack Spira

Cellda AB is a Swedish company founded in 2018 by Sören Nygren and Erik Wilander. The company is based in Uppsala, Sweden. Cellda® is a digital pathology company that aims to improve the accuracy and reproducibility of prostate cancer diagnosis. Cellda® provides automatic analysis of digital images of prostate biopsies to distinguish between normal and abnormal samples. The company's goal is to make the diagnosis of prostate cancer faster, more cost-effective, objective, and reproducible with the help of computerized image analysis of scanned microscope images from prostate samples. Accurate histological diagnosis of prostatic adenocarcinoma is an important issue worldwide, as it is the second most frequent malignancy after lung cancer in men worldwide, causing about 360,000 deaths. The CEO is Susanne Bredenberg.

Cellda AB is a Swedish company founded in 2018 by Sören Nygren and Erik Wilander. The company is based in Uppsala, Sweden. Cellda® is a digital pathology company that aims to improve the accuracy and reproducibility of prostate cancer diagnosis. Cellda® provides automatic analysis of digital images of prostate biopsies to distinguish between normal and abnormal samples. The company's goal is to make the diagnosis of prostate cancer faster, more cost-effective, objective, and reproducible with the help of computerized image analysis of scanned microscope images from prostate samples. Accurate histological diagnosis of prostatic adenocarcinoma is an important issue worldwide, as it is the second most frequent malignancy after lung cancer in men worldwide, causing about 360,000 deaths. The CEO is Susanne Bredenberg.

Cellda AB is a Swedish company founded in 2018 by Sören Nygren and Erik Wilander. The company is based in Uppsala, Sweden. Cellda® is a digital pathology company that aims to improve the accuracy and reproducibility of prostate cancer diagnosis. Cellda® provides automatic analysis of digital images of prostate biopsies to distinguish between normal and abnormal samples. The company's goal is to make the diagnosis of prostate cancer faster, more cost-effective, objective, and reproducible with the help of computerized image analysis of scanned microscope images from prostate samples. Accurate histological diagnosis of prostatic adenocarcinoma is an important issue worldwide, as it is the second most frequent malignancy after lung cancer in men worldwide, causing about 360,000 deaths. The CEO is Susanne Bredenberg.